Scienture (NASDAQ:SCNX) versus Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis

Scienture (NASDAQ:SCNX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Scienture has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.93, suggesting that its share price is 593% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Scienture and Vivos Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	1	0	2.00
Vivos Therapeutics	1	2	2	0	2.20

Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 262.14%. Vivos Therapeutics has a consensus price target of $2.58, suggesting a potential upside of 150.81%. Given Scienture’s higher possible upside, equities research analysts clearly believe Scienture is more favorable than Vivos Therapeutics.

Valuation & Earnings

This table compares Scienture and Vivos Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	39.14	-$41.51 million	($2.76)	-0.15
Vivos Therapeutics	$17.44 million	0.80	-$21.17 million	($2.07)	-0.50

Vivos Therapeutics has higher revenue and earnings than Scienture. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scienture and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.25%	-41.55%
Vivos Therapeutics	-121.37%	-849.22%	-96.11%

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.